This article has an addendum: The patient provided written informed consent.
Original article: Oncotarget. 2020; 11:2137–2140. 2137-2140. https://doi.org/10.18632/oncotarget.27598
. 2022 Nov 17;13:1245. doi: 10.18632/oncotarget.28312
Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
Javier Molina-Cerrillo
1,✉, Teresa Alonso-Gordoa
1, Alfredo Carrato
1, Enrique Grande
2
Javier Molina-Cerrillo
1Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
Find articles by Javier Molina-Cerrillo
Teresa Alonso-Gordoa
1Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
Find articles by Teresa Alonso-Gordoa
Alfredo Carrato
1Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
Find articles by Alfredo Carrato
1Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
2MD Anderson Cancer Center, Madrid, Spain
✉
Correspondence to: Javier Molina-Cerrillo, email : javier.molinace@gmail.com
Collection date 2022.
Copyright: © 2022 Molina-Cerrillo et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PMCID: PMC9671451 PMID: 36395352